Treating age-related macular degeneration - Interaction of VEGF-antagonists with their target

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 1127-1135

  Klettner, A ^a   Roider, J ^a  

^a UKS H   (Germany)

Author keywords

AMD; Lucentis; Pegaptanib; Ranibizumab; VEGF; VEGF trap

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BEVASIRANIB; HEPARAN SULFATE; HEPARIN; NEUROPILIN; PEGAPTANIB; RANIBIZUMAB; SIRNA 027; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; APTAMER; HYBRID PROTEIN; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; VEGF TRAP FUSION PROTEIN, RECOMBINANT; VEGF-TRAP FUSION PROTEIN, RECOMBINANT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; CORNEA NEOVASCULARIZATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; AGE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; RETINA MACULA DEGENERATION;

AGE FACTORS; AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; HUMANS; MACULAR DEGENERATION; MOLECULAR SEQUENCE DATA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 70349577355     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788922665     Document Type: Review

References (83)

1. Nowak, J.Z. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol. Rep., 2006, 58, 353-363. (Pubitemid 44111070)
2. Moreira, I.S.; Fernandes, P.A.; Ramos, M.J. Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med. Chem., 2007, 7, 223-245 . (Pubitemid 46403586)
3. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285, 1182-1186.
4. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219, 983-985.
5. Ferrara, N.; Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 1989, 161, 851-858 . (Pubitemid 19162712)
6. Muller, Y.A.; Christinger, H.W.; Keyt, B.A.; de Vos, A.M. The crystal structure of VEGF refined to 1.93 Angstrom resolution: multiple copy flexibility and receptor binding. Structure, 1997, 5, 1325-1338.
7. Vitt, U.A.; Hsu, S.Y.; Hsueh, A.J. Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol. Endocrinol., 2001, 15, 681-694.
8. Kasap, M.; Phylogenetic analysis of vascular endothelial growth factor diversity. Turk. J. Biol., 2005, 29, 217-227.
9. Carmeliet, P.; Ferrierea, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, A.; Harpal, K.; Eberhardt, C.; Declercq, C.; Moons, L.; Pawling, J.; Collen, D.; Risau, W.; Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380, 435-439. (Pubitemid 26102719)
10. Vincenti, V.; Cassano, C.; Rocchi, M.; Persico, G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation, 1996, 93, 1493-1495. (Pubitemid 26115412)
11. Holmes, D.I.R.; Zachary, I. The VEGF family: angiogenic factors in health and disease. Gen. Biol., 2005, 6, 209.
12. Plouët, J.; Moro, F.; Bertagnolli, S.; Coldeboeuf, N.; Mazarguil, H.; Clamens, S.; Bayard, F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem., 1997, 272, 13390-13396. (Pubitemid 27216772)
13. Bates, D.O.; Cui, T.G.; Doughty, J.M.; Winkler, M.; Sugiono, M.; Shields, J.D.; Peat, D.; Gillatt, D.A.; Harper, S.J. VEGF165b, an inhibitory splice variant of VEGF, is down-regulated in renal cell carcinoma. Cancer Res., 2002, 62, 4123-4131.
14. Woolard, J.; Wang, W.Y.; Bevan, H.S.; Qiu, Y.; Morbidelli, L.; Pritchard-Jones, R.; Cui, T.G.; Sugiono, M.; Waine, E.; Perrin, R.; Foster, R.; Digby-Bell, J.; Shields, J.D.; Whittles, C.E.; Mushens, R.E.; Gillatt, D.A.; Ziche, M.; Harper, S.J.; Bates, D.O. VEGF165b, an inhibitory VEGF splice variant: Mechanisms of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res., 2004, 64, 7822-7835.
15. Brandner, B.; Kurkela, R.; Vihko, P.; Kungl, A.J. Investigating the effect of VEGF glycosylation of glycosaminoglycan binding and protein folding. Biochem. Biophys. Res. Commun., 2006, 340, 836-839.
16. Keck, R.G.; Berleau, L.; Herris, R.; Keyt, B.A. Disulfide structure of the heparin binding domain in VEGF: Characterization of posttranslational modifications in VEGF. Arch. Biochem. Biophys., 1997, 344, 103-113.
17. Soker, S.; Takashima, S.; Miao, H.Q.; Neufeld, G.; Klagsbrun, M. Neuropilin-1is expressed by endothelial and tumor cells as an isoformspecific receptor for VEGF. Cell, 1998, 92, 735-745.
18. Fairbrother, W.J.; Champe, M.A.; Christinger, H.W.; Keyt, B.A.; Starovasnik, M.A. Solution structure of the heparin-binding domain of VEGF. Structure, 1998, 6, 637-648.
19. Gaspar, N.J.; Jue, R.A.; Puchacz, E.; deForest, N.; Schellenberger, U. Cysteine 116 participates in intermolecular bonding of the human VEGF121 homodimer. Arch. Biochem. Biophys., 2002, 404, 126-135.
20. Kondo, K.; Hiratsuka, S.; Subbalakshmi, E.; Matsushime, H.; Shibuya, M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene, 1998, 208, 297-305. (Pubitemid 28120941)
21. Kendall, R.L.; Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA, 1993, 90, 10705-10709. (Pubitemid 23347111)
22. Shibuya, M. Structure and dual function of VEGFR-1 (Flt-1). Int. J. Biochem. Cell Biol., 2001, 33, 409-420.
23. Blechman, J.M.; Lev, S.; Barg, J.; Eisenstein, M.; Vaks, B.; Vogel, Z.; Givol, D.; Yarden, Y. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell, 1995, 80, 103-113.
24. Shibuya, M.; Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Angiogenesis, 2006, 9, 225-2230.
25. de Vries, C.; Escobedo, J.A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 1992, 255, 989-991.
26. Guo, D.; Jia, Q.; Song, H.Y.; Warren, R.S.; Donner, D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem., 1995, 270, 6729-6733.
27. Ferrara, N. VEGF: Basic science and clinical progress. Endocr. Rev., 2004, 25, 581-611.
28. Barleon, B.; Sozzani, S.; Zhou, D.; Weich, H.A.; Mantovani, A.; Marmé, D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood, 1996, 87, 3336-3343. (Pubitemid 26115364)
29. Gille, H.; Kowalski, J., Li, B.; LeCouter, J.; Moffat, B.; Zioncheck, T.F.; Pelletier, N.; Ferrara, N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem., 2001, 276, 3222-3230 (Pubitemid 37411615)
30. Holmes, K.; Roberts, O.L.; Thomas, AM; Cross, MJ. VEGFR-2: structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal., 2007, 19, 2003-2012.
31. Fuh, G.; Li, B.; Crowley, C.; Cunningham, B.; Wells, J.A. Requirements for binding and signaling of the kinase domain receptor for VEGF. J. Biol. Chem., 1998, 273, 11197-11204.
32. Ruch, C.; Skiniotis, G.; Steinmetz, M.O.; Walz, T.; Ballmer-Hofer, K. Structure of a VEGF-VEGFR complex determined by electron microscopy. Nat. Struct. Mol. Biol., 2007, 14, 249-250. (Pubitemid 46355572)
33. Wiesmann, C.; Fuh, G.; Christinger, H.W.; Eigenbrot, C.; Wells, J.A.; de Vos, A.M. Crystal structure at 1.7 Angstrom resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell, 1997, 91, 695-704.
34. Keyt, B.A.; Nguyen, H.V.; Berleau, L.T.; Duarte, C.M.; Park, J.; Chen, H.; Ferrara, N. Identification of VEGF determinants for binding KDR and Flt-1 Receptors. J. Biol. Chem., 1996, 271, 5638-5646.
35. Kasap, M.; Sazci, A. The comparison of VEGFR-1-binding domain of VEGF-A with modelled VEGF-C sheds light on receptor specificity. J. Theor. Biol., 2008, 253, 446-451.
36. Starovasnik, M.A.; Christinger, H.W.; Wiesmann, C.; Champe, M.A.; de Vos, A.M.; Skelton, N. Solution structure of the VEGFbinding domain of Flt-1: Comparison of free and bound states. J. Mol. Biol., 1999, 293, 531-544. (Pubitemid 29512054)
37. Terman, B.I.; Carrion, M.E.; Kovacs, E.; Rasmussen, B.A.; Eddy, R.L.; Shows, T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 1991, 6, 1677-1683. (Pubitemid 21924273)
38. Chen, H.; Chédotal, A.; He, Z.; Goodman, C.S.; Tessier-Lavigne, M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron, 1997, 19, 547-559. (Pubitemid 27430744)
39. Pellet-Many, C.; Frankel, P.; Jia, H.; Zachary, I. Neuropilins: structure, function and role in disease. Biochem. J., 2008, 411, 211-226.
40. Gluzman-Poltorak, Z.; Cohen, T.; Herzog, Y.; Neufeld, G. Neuropilin- 2 and neuropilin-1 are receptors for the 165-amino acid form of VEGF and of PlGF-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J. Biol. Chem., 2000, 275, 18040-18045.
41. Pan, Q.; Chathery, Y.; Wu, Y.; Rathore, N.; Tong, R.K.; Peale, F.; Bagri, A.; Tessier-Lavigne, M.; Koch, AW; Watts, RJ. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol. Chem., 2007, 282, 24049-24056. (Pubitemid 47328044)
42. von Wronski, M.A.; Raju, N.; Pillai, R.; Bogdan, M.J.; Marinelli, E.R.; Nanpappan, P.; Ramalingan, K.; Arunachalam, T.; Eaton, S.; Linder, K.E.; Yan, F.; Pochon, S.; Tweedle, M.F.; Nunn, A.D. Tuftsin binds to neuropilin-1 through a sequence similar to that encoded by exon 8 of VEGF. J. Biol. Chem., 2006, 281, 5702-5710.
43. Jia, H.; Bagherzadeh, A.; Hartzoulakis, B.; Jarvis, A.; Löhr, M.; Shaikh, S.; Aquil, R.; Cheng, L.; Tickner, M.; Esposito, D.; Harris, R.; Driscoll, P.C.; Selwood, D.L.; Zachary, I. Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of VEGF exon 8 for NP-1 binding and Role of NP-1 in KDR signaling. J. Biol. Chem., 2006, 281, 13493-13502. (Pubitemid 43855262)
44. Fuh, G.; Garcia, K.C.; de Vos, AM. The interaction of Neuropilin-1 with VEGF and its receptor Flt-1. J. Biol. Chem., 2000, 275, 26690-26695.
45. Pan, Q.; Chanthery, Y.; Liang, W.C.; Stawicki, S.; Mak, J.; Rathore, N.; Tong, R.K.; Kowalski, J.; Yee, S.F.; Pacheco, G.; Ross, S.; Cheng, Z.; Le Couter, J.; Plowman, G.; Peale, F.; Koch, A.W.; Wu, Y.; Bagri, A.; Tessier-Lavigne, M.; Watts, R.J. Blocking NP-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell., 2007, 11, 53-67.
46. Wang, Y.; Fei, D.; Vandelaan, M.; Song, A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2005, 7, 335-345.
47. Esko, J.D.; Selleck, S.B. Order out of Chaos: Assembly of Ligand Binding Sites in Heparan Sufate. Annu. Rev. Biochem., 2002, 71, 435-471
48. Rabenstein, D.L. Heparin and heparan sulfate: structure and function. Nat. Prod. Rep., 2002, 19, 312-331.
49. Robinson, C.J.; Mulloy, B.; Gallagher, M.; Stringer, S.E. VEGF165-binding sites within Heparan Sulfate encompass two highly sulfated domains and can be liberated by K5 lysase. J. Biol. Chem., 2006, 281, 1731-1740 .
50. Cohen, T.; Gitay-Goren, H.; Sharon, R.; Shibuya, M.; Halaban, R.; Levi, B.U.; Neufeld, G. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates fro efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem., 1995, 270, 11322-11326.
51. Gitay-Goren, H.; Cohen, T.; Tessler, S.; Soker, S.; Gengrinovitch, S.; Rockwell, P.; Klagsbrun, M.; Levi, B.Z.; Neufeld, G. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J. Biol. Chem., 1996, 271, 5519-5523. (Pubitemid 26084453)
52. Hamma-Kourbali, Y.; Vassy, R.; Starzec, A.; Le Meuth-Metzinger, V.; Oudar, O.; Bagheri-Yarmand, R.; Perret, G.; Crépin, M. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165) KDR Complexes. J. Biol. Chem., 2001, 276, 39748-39754. (Pubitemid 37391381)
53. Mamluk, R.; Gechtman, Z.; Kutcher, M.E.; Gasiunas, N.; Gallagher, J.; Klagsbrun, M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J. Biol. Chem., 2002, 277, 24818-24825. (Pubitemid 34952014)
54. Ruhrberg, C.; Gerhardt, H.; Golding, M.; Watson, R.; Ioannidou, S.; Fujisawa, H.; Betsholtz, C.; Shima, D.T. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev., 2002, 16, 2684-2698.
55. Gengrinovitch, S.; Berman, B.; David, G.; Witte, L.; Neufeld, G.; Ron, D. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J. Biol. Chem., 1999, 274, 10816-10822. (Pubitemid 129528283)
56. Kim, K.J.; Li,B.; Houck, K.; Winer, J.; Ferrara, N. The VEGF proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors, 1992, 7, 53-64.
57. Kim, K.J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H.S.; Ferrara, N. Inhibition of VEGF-induced angiogenesis suppresses tumour growth in vivo. Nature, 1993, 362, 841-844.
58. Presta, L.G.; Chen, H.; O'Connor, S.J.; Chisholm, V.; Meng, G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanisation of an anti- VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57, 4593-4599.
59. European Medicines Agency. European Public Assessment Report (EPAR) on Avastin, Scientific Discussion, 2005, 1-61.
60. Krämer, I.; Lipp, H.P. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J. Clin. Invest., 2007, 32, 1-14. (Pubitemid 46213936)
61. Gatto, B.; Cavalli, M. From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy. Anticancer Agents Med. Chem., 2006, 6, 287-301. (Pubitemid 44027697)
62. Park, J.E.; Keller, G.A.; Ferrara, N. The VEGF-Isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix bound VEGF. Mol. Biol. Cell., 1993, 4, 1317-1326.
63. Chen, Y.; Wiesmann, C.; Fuh, G.; Li, B.; Christinger, H.W.; McKay, P.; de Vos, A.M.; Lowman, H.B. Selection and analysis of an optimized anti- VEGF antibody: crystal structure of an affinity-matured Fab in Complex with Antigen. J. Mol. Biol., 1999, 293, 865-881.
64. Muller, Y.A.; Chen, Y.; Christinger, H.W.; Cunningham, B.C.; Lowman, H.B.; de Vos, A.M. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure, 1998, 6, 1153-1167.
65. Ferrara, N.; Damico, L.; Shams, N.; Lowman, H.; Kim, R. Development of ranibizumab, an anti - VEGF antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina, 2006, 26, 859-870. (Pubitemid 44547437)
66. Klettner, A.; Roider, J. Comparison of Bevacizumab, Ranibizumab and Pegaptanib in vitro: efficiency and possible additional pathways. Invest. Ophthalmol. Vis. Sci., 2008, 49, 4523-4527.
67. th edit., National Institutes of Health, 1987.
68. Deudero, J.J.P.; Caramelo, C.; Castellanos, M.C.; Neria, F.; Fernandez- Sanchez, R.; Calabia, O.; Penate, S.; Gonzalez-Pacheco, F.R. Induction of Hypoxia-inducible Factor 1 alpha gene expression by VEGF. J. Biol. Chem., 2008, 283, 11435-11444.
69. Ishida, S.; Usui, T.; Yamashiro, K.; Kaji, Y.; Amano, S.; Ogura, Y.; Hida, T.; Oguchi, Y.; Amabti, J.; Miller, J.W.; Gragoudas, E.S.; Ng, Y.S.; D'Amore, P.A.; Shima, D.T.; Adamis, A.P. VEGF164 mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med., 2003, 198, 483-489.
70. Ruckman, J.; Green, L.S.; Beeson, J.; Waugh, S.; Gillette, W.L.; Henninger, D.D.; Claesson-Welsh, L.; Janjic, N. 2'Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of VEGF. J. Biol. Chem., 1998, 273, 20556-20567.
71. Lee, J.H.; Canny, M.D.; De Erkenez, A.; Krilleke, D.; Ng, Y.H.; Shima, D.T.; Pardi, A.; Jucker, F. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. USA, 2005, 102, 18902-18907. (Pubitemid 43049539)
72. Bozza, M.; Sheardy, R.D.; Dilone, E.; Scypinski, S.; Galazka, M. Characterization of the secondary structure and stability of an RNA aptamer that binds VEGF. Biochemistry, 2006, 45, 7639-7643.
73. Lee, J.H.; Jucker, F.; Pardi, A. Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-targeting aptamer, Macugen. FEBS Lett., 2008, 582, 1835-1839.
74. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, W.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J.P.; Daly, T.; Wiegand, S.J.; Yancopoulos, G.D.; Rudge, J.S. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA, 2002, 99, 11393-11398.
75. Nguyen, Q.D.; Shah, S.M.; Hafiz, G.; Quinlan, E.; Sung, J.; Chu, K.; Cedarbaum, J.M.; Campochiaro, P.A.; CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered VEGF Trap for treatment in patients with CNV due to AMD. Ophthalmology, 2006, 113, 1522-1535.
76. Rudge, J.S.; Holash, J.; Hylton, D.; Russell, M.; Jiang, S.; Leidich, R.; Papadopoulos, N.; Pyles, E.; Torri, A.; Wiegand, S.J.; Thurston, G.; Stahl, N.; Yancopoulos, G.D. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl. Acad. Sci. USA, 2007, 104, 18363-18370 .
77. Dykxhoorn, D.M.; Novina, C.D.; Sharp, P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Cell Biol., 2007, 4, 457-467.
78. Shen, J.; Samul, R.; Silva, R.L.; Akiyama, H.; Liu, H.; Saishin, Y.; Hackett, S.F.; Zinnen, S.; Kossen, K.; Fosnaugh, K.; Vargeese, C.; Gomez, A.; Bouhana, K.; Aitchison, R.; Pavco, P.; Campochiaro, P.A. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther., 2006, 13, 225-234.
79. Fuh, G.; Wu, P.; Liang, W.C.; Ultsch, M.; Lee, C.V.; Moffat, B.; Wiesmann, C. Structure-function studies of two synthetic anti- VEGF Fabs and comparison with the Avastin Fab. J. Biol. Chem., 2006, 281, 6625-6631.
80. Dejneka, N.S.; Wan, S.; Bond, O.S.; Kornbrust, D.J.; Reich, S.J. Ocular biodistribution of bevasiranib following a single intravitreal injection into rabbit eyes. Mol. Vis., 2008, 14, 997-1005.
81. Reich, S.L.; Fosnot, R.; Kuroki, A.; Tang, W.; Yang, X.; Maguire, A.M.; Bennett, J.; Tolentino, M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis., 2003, 9, 210-216.
82. Kleinman, M.E.; Yamada, K.; Takeda, A.; Chandrasekaran, V.; Nozaki, M.; Baffi, J.Z.; Albuquerque, R.J.; Yamasaki, S.; Itaya, M.; Pan, Y.; Appukuttan, B.; Gibbs, D.; Yang, Z.; Karikó, K.; Ambati, B.K.; Wilgus, T.A.; DiPietro, L.A.; Sakurai, E.; Zhang, K.; Smith, J.R.; Taylor, E.W.; Ambati, J. Sequence- and targetindependent angiogenesis suppression by siRNA via TRL3. Nature, 2008, 452, 591-597.
83. Rehli, M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol., 2002, 23, 375-378. (Pubitemid 34804626)